Arazine (N-Acetyl-S-farnesyl-L-cysteine) is a cell-permeable modulator of G protein and G-protein coupled receptor signaling. Arazine can be a a substrate for isoprenylcysteine methyltransferase by competing with prenylated G protein or its receptors site.

Liquid

Arazine (2 hours) inhibits ATPγS induced CXCL1, CXCL8 and CCL2 production as a dose-dependent manner in HMEC-1 cell.
Arazine (10–100 μM;8 hours) significantly affects the HMEC-1 cell viability as measured by trypan blue exclusion in HMEC-1 cell.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Arazine (AFC) (2,000 μg/20 μl; applied on ear) produces a dose-dependent inhibition of the TPA-induced edema, with the maximal reduction of edema approaching 73%, with a 50% effective dose (ED₅₀) of 55±12 μg/20 μl.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature or refrigerated transportation.

Solution, -20°C, 2 years

• [1]. Gordon JS, et al. Topical N-acetyl-S-farnesyl-L-cysteine inhibits mouse skin inflammation, and unlike dexamethasone, its effects are restricted to the application site.J Invest Dermatol. 2008 Mar;128(3):643-54. Epub 2007 Sep 20.  [Information]

  [2]. Adhami K, et al. N-acetyl-S-farnesyl-l-cysteine suppresses chemokine production by human dermal microvascular endothelial cells.Exp Dermatol. 2012 Sep;21(9):700-5.  [Information]